NIH Topic: A New Therapy for the Warfighter

We believe that an advanced wound therapy will not only enable the warfighter to persist in battle but may also have significant commercial applications. The primary customers for the first product will include general surgeons, burn and wound care unitdirectors and staff, and affiliated medical personnel involved with patient management of acute and chronic wound care settings. We anticipate that a relatively broad spectrum of wounds will respond favorably to this treatment based on the longstandingscientific literature (e.g. TK Hunt et al) that identified tissue oxygen levels as a crucial determinant of overall wound healing as well as its instrumental role for substrate formation including collagen synthesis. Burns, surgical wounds, skin flaps,minor cuts, abrasions, and chronic wounds are all expected to benefit from such treatment, albeit with differentiated treatment regimens (dosage and frequency). In the U.S. these combined segments represent the potential for approximately $500 million inrevenues for a moderately priced product, i.e. less than $100.